Skip to content
TrialScanner

NCT00061633

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Phase 2CompletedCPIXLead

Registry record

Lead sponsor
Cumberland Pharmaceuticals
Conditions
Infections, Gram-Positive Bacterial; Abscess; Burns; Cellulitis; Ulcer
Primary completion
Jan 2004Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00061633 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00061633: Phase 2 Trial of TD 6424... | TrialScanner